1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Beta Blockers (Migraine) - Forecast and Market Analysis to 2023

Beta Blockers (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Among the various prophylaxis therapy classes for migraine, beta blockers are highly effective and are the most widely used class of drugs for the prophylaxis of migraine. Beta blockers were primarily developed for controlling cardiac symptoms but were coincidentally found to have an effect on migraine prevention. They have been used as migraine treatment since the 1970s. Their mechanism of action for preventing migraine is not clear, but beta receptors have been shown to be present in the pial vessel of the brain. The possible mechanisms of action of beta blockers include reducing the neuronal firing rate of noradrenergic neurons in the locus coeruleus, regulation of PAG neurons firing rate and possible inhibition of 5-HT2C and 5-HT2B receptor subtypes.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Beta blockers including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Beta blockers for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Beta blockers performance
- Obtain sales forecast for Beta blockers from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Beta Blockers (Migraine) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Prognosis 16
3.2 Symptoms 16
3.2.1 Premonitory Phase 17
3.2.2 Aura Phase 17
3.2.3 Headache Phase 18
3.2.4 Postdrome Phase 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Treatment 23
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 25
6 Beta Blockers 27
6.1 Overview 27
6.2 Efficacy 28
6.3 Safety 29
6.4 SWOT Analysis 29
6.5 Forecast 29
7 Appendix 31
7.1 Bibliography 31
7.2 Abbreviations 34
7.3 Methodology 35
7.4 Forecasting Methodology 35
7.4.1 Diagnosed Migraine Patients 35
7.4.2 Percent Drug-treated Patients 35
7.4.3 General Pricing Assumptions 36
7.4.4 Individual Drug Assumptions 37
7.4.5 Generic Erosion 37
7.5 Physicians and Specialists Included in this Study 38
7.6 Survey of Prescribing Physicians 39
7.7 About the Authors 40
7.7.1 Author 40
7.7.2 Reviewer 40
7.7.3 Global Head of Healthcare 41
7.8 About GlobalData 42
7.9 Disclaimer 42

1.1 List of Tables

Table 1: Classification of Migraine Subtypes 13
Table 2: Diagnostic Criteria for Migraine with Aura 17
Table 3: Diagnostic Criteria for Migraine without Aura 18
Table 4: Treatment Guidelines for Migraine 20
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013 21
Table 6: Product Profile - Beta Blockers 28
Table 7: Beta Blockers SWOT Analysis, 2013 29
Table 8: Global Sales Forecasts ($m) for Beta Blockers, 2012-2023 30
Table 9: Physicians Surveyed, By Country 39

1.2 List of Figures

Figure 1: Migraine Treatment Algorithm in the 7MM 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • May 2016
  • by Global Data

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025 Summary GlobalData estimates sales of Heart Failure (HF) therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Anti-Infective and Therapy Market in the US - Forecast

  • December 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Therapy Market and Diabetes Statistics in the UK

  • November 2016
    9 pages
  • Therapy  

    Statins  

    Diabetes  

  • United Kingdom  

View report >

Related Market Segments :

Beta-Blocker
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.